Patricia L Allen - Net Worth and Insider Trading

Patricia L Allen Net Worth

The estimated net worth of Patricia L Allen is at least $289,409 dollars as of 2024-11-13. Patricia L Allen is the VP of Finance and Treasurer of Alnylam Pharmaceuticals Inc and owns about 1,070 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $287,777. Patricia L Allen is the CFO of Zafgen Inc and owns about 1,649 shares of Zafgen Inc (ZFGN) stock worth over $1,633. Patricia L Allen is also the Director of Deciphera Pharmaceuticals Inc and owns about 0 shares of Deciphera Pharmaceuticals Inc (DCPH) stock worth over $0. Details can be seen in Patricia L Allen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Patricia L Allen has not made any transactions after 2020-06-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Patricia L Allen

To

Patricia L Allen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Patricia L Allen owns 5 companies in total, including Deciphera Pharmaceuticals Inc (DCPH) , Larimar Therapeutics Inc (LRMR) , and Alnylam Pharmaceuticals Inc (ALNY) among others .

Click here to see the complete history of Patricia L Allen’s form 4 insider trades.

Insider Ownership Summary of Patricia L Allen

Ticker Comapny Transaction Date Type of Owner
DCPH Deciphera Pharmaceuticals Inc 2020-06-05 director
LRMR Larimar Therapeutics Inc 2016-03-31 Chief Financial Officer
ALNY Alnylam Pharmaceuticals Inc 2006-01-01 VP of Finance and Treasurer
LIMIT LIMIT 2020-12-22 director
LIMIT LIMIT 2020-12-22 director

Patricia L Allen Latest Holdings Summary

Patricia L Allen currently owns a total of 3 stocks. Among these stocks, Patricia L Allen owns 1,070 shares of Alnylam Pharmaceuticals Inc (ALNY) as of January 1, 2006, with a value of $287,777 and a weighting of 99.44%. Patricia L Allen owns 1,649 shares of Zafgen Inc (ZFGN) as of July 26, 2016, with a value of $1,633 and a weighting of 0.56%. Patricia L Allen also owns 0 shares of Deciphera Pharmaceuticals Inc (DCPH) as of June 5, 2020, with a value of $0 and a weighting of 0%.

Latest Holdings of Patricia L Allen

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALNY Alnylam Pharmaceuticals Inc 2006-01-01 1,070 268.95 287,777
ZFGN Zafgen Inc 2016-07-26 1,649 0.99 1,633
DCPH Deciphera Pharmaceuticals Inc 2020-06-05 0 25.59 0

Holding Weightings of Patricia L Allen


Patricia L Allen Form 4 Trading Tracker

According to the SEC Form 4 filings, Patricia L Allen has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 0 shares on January 1, 2006, which brought Patricia L Allen around $0.

According to the SEC Form 4 filings, Patricia L Allen has made a total of 0 transactions in Zafgen Inc (ZFGN) over the past 5 years. The most-recent trade in Zafgen Inc is the acquisition of 1,333 shares on July 26, 2016, which cost Patricia L Allen around $49,920.

According to the SEC Form 4 filings, Patricia L Allen has made a total of 2 transactions in Deciphera Pharmaceuticals Inc (DCPH) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Deciphera Pharmaceuticals Inc is the sale of 12,000 shares on June 5, 2020, which brought Patricia L Allen around $691,440.

Insider Trading History of Patricia L Allen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Patricia L Allen Trading Performance

GuruFocus tracks the stock performance after each of Patricia L Allen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Patricia L Allen is 9.06%. GuruFocus also compares Patricia L Allen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Patricia L Allen within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Patricia L Allen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Patricia L Allen

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -1.29 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -1.28 LIMIT LIMIT LIMIT LIMIT LIMIT

Patricia L Allen Ownership Network

Ownership Network List of Patricia L Allen

No Data

Ownership Network Relation of Patricia L Allen

Insider Network Chart

Patricia L Allen Owned Company Details

What does Deciphera Pharmaceuticals Inc do?

Who are the key executives at Deciphera Pharmaceuticals Inc?

Patricia L Allen is the director of Deciphera Pharmaceuticals Inc. Other key executives at Deciphera Pharmaceuticals Inc include SVP & Regulatory & Quality Jama Pitman , Chief Commercial Officer Daniel C. Martin , and Chief Financial Officer Thomas Patrick Kelly .

Deciphera Pharmaceuticals Inc (DCPH) Insider Trades Summary

Over the past 18 months, Patricia L Allen made no insider transaction in Deciphera Pharmaceuticals Inc (DCPH). Other recent insider transactions involving Deciphera Pharmaceuticals Inc (DCPH) include a net sale of 23,797 shares made by Daniel C. Martin , a net sale of 12,184 shares made by Matthew L Sherman , and a net sale of 9,198 shares made by Thomas Patrick Kelly .

In summary, during the past 3 months, insiders sold 0 shares of Deciphera Pharmaceuticals Inc (DCPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 105,002 shares of Deciphera Pharmaceuticals Inc (DCPH) were sold and 10,000 shares were bought by its insiders, resulting in a net sale of 95,002 shares.

Deciphera Pharmaceuticals Inc (DCPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Deciphera Pharmaceuticals Inc Insider Transactions

No Available Data

Patricia L Allen Mailing Address

Above is the net worth, insider trading, and ownership report for Patricia L Allen. You might contact Patricia L Allen via mailing address: C/o Deciphera Pharmaceuticals, Inc, 200 Smith Street, Waltham Ma 02451.